Who we are
Roboleo & Co has been successfully developing new products and services for Pharma and Med-tech clients since 2004.
Rob Whitemore
Educated in Business Studies and Marketing, Rob has spent over 30 years’ profitably building multinational and early stage businesses within Pharmaceutical, Medical Devices, Diagnostic and Consumer Healthcare market sector. Read More »
Having previously held senior management/director roles with leading companies (including RPR, Pharmacia and Unilever), Rob founded Roboleo & Co in 2004 with the specific focus on commercialisation of innovative technologies. Over the years he led the development of the company to create one of the first specialist Market Access consultancies and has built a strong team of thought leaders to ensure they consistently deliver innovative, bespoke solutions - and have the track-record to prove it. Rob is a trained NICE META Facilitator.
+44 (0) 7855 367380|
Email Rob|
Iain Claxton
Iain has been a partner with Roboleo since 2008 and has worked in the Pharmaceutical Industry for over 30 years. His early career was spent in the UK working with Merck before moving to GSK, where he held a number of senior roles in Sales and Marketing. He has also spent time working throughout Europe, delivering client projects in different therapeutic areas. Read More »
Since leaving GSK, he has worked as a consultant and during his time at Roboleo has helped develop the company’s Health Economics and HTA franchise. He currently works with existing and new clients advising on HTA strategies and working with our internal teams of experts to ensure seamless delivery of projects.
Iain is also responsible for setting up and managing Roboleo’s Health Economics training which has been hugely successful and is now a familiar event in the calender, having been attended by many industry professionals over the last 8 years.
+44 (0) 7885 444274|
Email Iain|
Prof Chris Bojke PhD
Chris is Chair in Health Economics (specialising in HTA) at the University of Leeds. He is an empirical health economist specialising in the analysis of observational datasets and their role in HTA. He combines a technical expertise with an ability to understand the bigger picture, specifically where and how new technologies can demonstrate their economic argument, early identification of the challenges of demonstrating that argument and knowing which elements of an argument to enhance and those which should be avoided within an economic evaluation framework. Read More »
Previous positions include Senior Research Fellow at the Centre of Health Economics (CHE) at the University of York and a director of a leading international health economic consultancy.
Chris joined Roboleo & Co in 2009, and as the Company’s lead health economist, he has successfully led numerous HTA submissions and Pricing & Reimbursement projects, including the first ATMP stem cell therapy to be considered through the NICE single technology appraisal (STA) process.
Prof Nils Gutacker PhD
Nils is Professor in the Health Policy Team at the Centre for Health Economics (CHE), University of York. He holds a PhD in Economics and a MSc in Health Economics, both from the University of York, and a BSc in Health Care Management from the University of Duisburg-Essen, Germany. Read More »
Nils joined CHE in 2009 and his research focuses on unwarranted variations in health care provision, performance assessment of health care providers, measurement of health care quality using patient-reported outcome measures (PROMs), and the cost-effectiveness of (non-)financial incentives. He has also a member of the German expert council for the development of the health and care system (Sachverständigenrat Gesundheit & Pflege - SVR).
He has been a consultant to Roboleo & Co since 2015 and has worked on a wide of variety of strategic projects, HTA submissions and modelling projects for UK and European markets.
Louise Crathorne MSc
In addition to her work at Roboleo Louise has over eight years’ experience as an academic researcher at the University of Exeter Medical School specialising in health technology assessment and health economics, as well as experience of using evidence synthesis and budget impact modelling in local decision making in a clinical commissioning group (CCG). Read More »
The majority of my academic experience has been as a health technology assessment analyst for the Peninsula Technology Assessment Group (PenTAG), one of 10 teams conducting research to support the work of the UK National Institute for Health and Care Excellence (NICE) HTA programme. This included systematic reviews of diagnostic test accuracy, systematic reviews of clinical and cost effectiveness, and the critique and development of de novo health economic models.
In addition, she has experience of using evidence synthesis in the local decision-making process through her role as Clinical Evidence Scientist at the North East and West (NEW) Devon CCG, conducting rapid reviews of both interventions (without NICE guidance), surgical procedures to summarise available clinical and cost-effectiveness evidence as well as conducting budget impact analyses.
Louise’s consultancy experience includes:
- Preparation of regulatory documents (development of trial protocols, investigator brochures, clinical trial reports and regulatory submission packages for submission to the US FDA and EMA)
- Development of HTA dossiers for submission to UK policy making bodies (NICE, SMC, AWMSG and also submission to policy making bodies in The Netherlands, and Italy
- Preparation of communications including core/global value dossier (applying evidence synthesis methodology); advanced budgetary notifications; formulary packs; primary publications; slide decks; conference newsletters; preparation of materials for satellite symposia; and advisory board meetings
Louise holds an MSc in Health Economics and Health Policy from the University of Birmingham (2014), and a BA in English Language and Literature from the University of Swansea.
This team is supported by a network of talented individuals from industry and academia.
They enable us to offer the functional, market and therapeutic category expertise necessary across Europe and North America.
